148 related articles for article (PubMed ID: 37934001)
1. SUV39H1 Ablation Enhances Long-term CAR T Function in Solid Tumors.
López-Cobo S; Fuentealba JR; Gueguen P; Bonté PE; Tsalkitzi K; Chacón I; Glauzy S; Bohineust A; Biquand A; Silva L; Gouveia Z; Goudot C; Perez F; Saitakis M; Amigorena S
Cancer Discov; 2024 Jan; 14(1):120-141. PubMed ID: 37934001
[TBL] [Abstract][Full Text] [Related]
2. Disruption of SUV39H1-Mediated H3K9 Methylation Sustains CAR T-cell Function.
Jain N; Zhao Z; Koche RP; Antelope C; Gozlan Y; Montalbano A; Brocks D; Lopez M; Dobrin A; Shi Y; Gunset G; Giavridis T; Sadelain M
Cancer Discov; 2024 Jan; 14(1):142-157. PubMed ID: 37934007
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic reprogramming of CAR T cells for in vivo functional persistence against solid tumors.
Saitakis M
Genes Immun; 2024 Feb; ():. PubMed ID: 38388813
[TBL] [Abstract][Full Text] [Related]
4. The epigenetic control of stemness in CD8
Pace L; Goudot C; Zueva E; Gueguen P; Burgdorf N; Waterfall JJ; Quivy JP; Almouzni G; Amigorena S
Science; 2018 Jan; 359(6372):177-186. PubMed ID: 29326266
[TBL] [Abstract][Full Text] [Related]
5. Deleting SUV39H1 in CAR-T cells epigenetically enhances the antitumor function.
Wang Y; Zhao G; Wang S; Li N
MedComm (2020); 2024 May; 5(5):e552. PubMed ID: 38645666
[TBL] [Abstract][Full Text] [Related]
6. [Construction and function of Glypican-3-targeted fourth-generation chimeric antigen receptor T cells (secreting IL-7 and CCL19)].
Huang W; Liu Y; Hu Y; Gao J
Sheng Wu Gong Cheng Xue Bao; 2020 May; 36(5):979-991. PubMed ID: 32567281
[TBL] [Abstract][Full Text] [Related]
7. Chimeric antigen receptor modified T cell (CAR-T) co-expressed with ICOSL-41BB promote CAR-T proliferation and tumor rejection.
Hu W; Huang X; Huang X; Chen W; Hao L; Chen Z
Biomed Pharmacother; 2019 Oct; 118():109333. PubMed ID: 31545280
[TBL] [Abstract][Full Text] [Related]
8. Histone lysine methyltransferase SUV39H1 is a potent target for epigenetic therapy of hepatocellular carcinoma.
Chiba T; Saito T; Yuki K; Zen Y; Koide S; Kanogawa N; Motoyama T; Ogasawara S; Suzuki E; Ooka Y; Tawada A; Otsuka M; Miyazaki M; Iwama A; Yokosuka O
Int J Cancer; 2015 Jan; 136(2):289-98. PubMed ID: 24844570
[TBL] [Abstract][Full Text] [Related]
9. Genetic Modification Strategies to Enhance CAR T Cell Persistence for Patients With Solid Tumors.
DeRenzo C; Gottschalk S
Front Immunol; 2019; 10():218. PubMed ID: 30828333
[TBL] [Abstract][Full Text] [Related]
10. Improving CAR T-Cell Persistence.
Pietrobon V; Todd LA; Goswami A; Stefanson O; Yang Z; Marincola F
Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639168
[TBL] [Abstract][Full Text] [Related]
11. Selectively targeting myeloid-derived suppressor cells through TRAIL receptor 2 to enhance the efficacy of CAR T cell therapy for treatment of breast cancer.
Nalawade SA; Shafer P; Bajgain P; McKenna MK; Ali A; Kelly L; Joubert J; Gottschalk S; Watanabe N; Leen A; Parihar R; Vera Valdes JF; Hoyos V
J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34815355
[TBL] [Abstract][Full Text] [Related]
12. Secretion of 4-1BB Ligand Crosslinked to PD-1 Checkpoint Inhibitor Potentiates Chimeric Antigen Receptor T Cell Solid Tumor Efficacy.
Dunn ZS; Qu Y; MacMullan M; Chen X; Cinay G; Wang P
Hum Gene Ther; 2023 Nov; 34(21-22):1145-1161. PubMed ID: 36851890
[TBL] [Abstract][Full Text] [Related]
13. Role for tyrosine phosphorylation of SUV39H1 histone methyltransferase in enhanced trimethylation of histone H3K9 via neuregulin-1/ErbB4 nuclear signaling.
Nakajo H; Ishibashi K; Aoyama K; Kubota S; Hasegawa H; Yamaguchi N; Yamaguchi N
Biochem Biophys Res Commun; 2019 Apr; 511(4):765-771. PubMed ID: 30833073
[TBL] [Abstract][Full Text] [Related]
14. A safe and potent anti-CD19 CAR T cell therapy.
Ying Z; Huang XF; Xiang X; Liu Y; Kang X; Song Y; Guo X; Liu H; Ding N; Zhang T; Duan P; Lin Y; Zheng W; Wang X; Lin N; Tu M; Xie Y; Zhang C; Liu W; Deng L; Gao S; Ping L; Wang X; Zhou N; Zhang J; Wang Y; Lin S; Mamuti M; Yu X; Fang L; Wang S; Song H; Wang G; Jones L; Zhu J; Chen SY
Nat Med; 2019 Jun; 25(6):947-953. PubMed ID: 31011207
[TBL] [Abstract][Full Text] [Related]
15. CAR-T Cell Performance: How to Improve Their Persistence?
López-Cantillo G; Urueña C; Camacho BA; Ramírez-Segura C
Front Immunol; 2022; 13():878209. PubMed ID: 35572525
[TBL] [Abstract][Full Text] [Related]
16. RFX1 regulates CD70 and CD11a expression in lupus T cells by recruiting the histone methyltransferase SUV39H1.
Zhao M; Wu X; Zhang Q; Luo S; Liang G; Su Y; Tan Y; Lu Q
Arthritis Res Ther; 2010; 12(6):R227. PubMed ID: 21192791
[TBL] [Abstract][Full Text] [Related]
17. CRISPR/Cas9: A Powerful Strategy to Improve CAR-T Cell Persistence.
Wei W; Chen ZN; Wang K
Int J Mol Sci; 2023 Aug; 24(15):. PubMed ID: 37569693
[TBL] [Abstract][Full Text] [Related]
18. Tissue-resident memory CAR T cells with stem-like characteristics display enhanced efficacy against solid and liquid tumors.
Jung IY; Noguera-Ortega E; Bartoszek R; Collins SM; Williams E; Davis M; Jadlowsky JK; Plesa G; Siegel DL; Chew A; Levine BL; Berger SL; Moon EK; Albelda SM; Fraietta JA
Cell Rep Med; 2023 Jun; 4(6):101053. PubMed ID: 37224816
[TBL] [Abstract][Full Text] [Related]
19. CD33-Specific Chimeric Antigen Receptor T Cells with Different Co-Stimulators Showed Potent Anti-Leukemia Efficacy and Different Phenotype.
Li S; Tao Z; Xu Y; Liu J; An N; Wang Y; Xing H; Tian Z; Tang K; Liao X; Rao Q; Wang M; Wang J
Hum Gene Ther; 2018 May; 29(5):626-639. PubMed ID: 29409351
[TBL] [Abstract][Full Text] [Related]
20. Integrative Bulk and Single-Cell Profiling of Premanufacture T-cell Populations Reveals Factors Mediating Long-Term Persistence of CAR T-cell Therapy.
Chen GM; Chen C; Das RK; Gao P; Chen CH; Bandyopadhyay S; Ding YY; Uzun Y; Yu W; Zhu Q; Myers RM; Grupp SA; Barrett DM; Tan K
Cancer Discov; 2021 Sep; 11(9):2186-2199. PubMed ID: 33820778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
